All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jonathan Bond, Systems Biology Ireland, Dublin, IE, about the diagnosis and treatment of interface acute leukemias.
T/myeloid interface acute leukemias
Jonathan Bond discusses the biology and development of interface acute leukemias. He describes the incorporation of genome analyses and bioinformatics in disease characterization. He also talks about the finding of a study that used Iterative Clustering and Guide-gene Selection (ICGS) to analyze acute leukemia. He concludes by explaining treatment choices could be determined by the findings of genomic analyses.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox